SG Americas Securities LLC Reduces Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

SG Americas Securities LLC lowered its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSMGet Rating) by 73.8% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,450 shares of the company’s stock after selling 23,760 shares during the quarter. SG Americas Securities LLC’s holdings in Axsome Therapeutics were worth $324,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Axsome Therapeutics by 27.7% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,827 shares of the company’s stock worth $158,000 after purchasing an additional 831 shares during the last quarter. Kestra Advisory Services LLC increased its position in shares of Axsome Therapeutics by 53.4% during the first quarter. Kestra Advisory Services LLC now owns 9,595 shares of the company’s stock worth $397,000 after purchasing an additional 3,341 shares in the last quarter. Peregrine Capital Management LLC grew its position in Axsome Therapeutics by 38.9% during the 1st quarter. Peregrine Capital Management LLC now owns 165,656 shares of the company’s stock worth $6,857,000 after purchasing an additional 46,358 shares during the last quarter. DekaBank Deutsche Girozentrale increased its position in shares of Axsome Therapeutics by 10.0% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 14,350 shares of the company’s stock valued at $574,000 after acquiring an additional 1,300 shares during the period. Finally, Financial Consulate Inc. purchased a new stake in Axsome Therapeutics in the first quarter valued at approximately $201,000. Institutional investors own 54.96% of the company’s stock.

Axsome Therapeutics Price Performance

Axsome Therapeutics stock opened at $56.82 on Tuesday. Axsome Therapeutics, Inc. has a 12 month low of $20.63 and a 12 month high of $71.98. The company has a market cap of $2.21 billion, a price-to-earnings ratio of -14.49 and a beta of 1.75. The company has a current ratio of 2.44, a quick ratio of 2.20 and a debt-to-equity ratio of 6.15. The business’s 50 day simple moving average is $51.42 and its 200 day simple moving average is $41.82.

Axsome Therapeutics (NASDAQ:AXSMGet Rating) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($1.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.19) by $0.13. The company had revenue of $8.82 million for the quarter, compared to analysts’ expectations of $9.59 million. During the same quarter in the prior year, the firm earned ($0.86) EPS. Sell-side analysts forecast that Axsome Therapeutics, Inc. will post -4.24 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on AXSM shares. Jefferies Financial Group reduced their price target on Axsome Therapeutics from $92.00 to $90.00 and set a “buy” rating for the company in a research report on Friday, September 30th. Cantor Fitzgerald cut their price objective on shares of Axsome Therapeutics from $64.00 to $54.00 in a research report on Wednesday, August 10th. Morgan Stanley raised their price objective on shares of Axsome Therapeutics from $71.00 to $74.00 and gave the company an “equal weight” rating in a research note on Friday, October 14th. Loop Capital initiated coverage on shares of Axsome Therapeutics in a research note on Tuesday, November 1st. They issued a “buy” rating and a $95.00 price target on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $210.00 price target on shares of Axsome Therapeutics in a report on Tuesday, October 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, Axsome Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $104.64.

Axsome Therapeutics Profile

(Get Rating)

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation.

Recommended Stories

Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSMGet Rating).

Institutional Ownership by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.